Vitiligo as durvalumab's immune-related adverse event in lung cancer
Med Clin (Barc). 2022 Apr 8;158(7):341-342.
doi: 10.1016/j.medcli.2021.07.024.
Epub 2021 Oct 19.
[Article in
English,
Spanish]
Affiliations
- 1 Medical Oncology Department, Hospital Universitario Infanta Leonor, Gran vía del este, 80, 28031 Madrid, Spain; Universidad Complutense de Madrid, Madrid, Spain. Electronic address: jacobo.rogado@gmail.com.
- 2 Dermatology Department, Hospital Universitario Infanta Leonor, Gran vía del este, 80, 28031 Madrid, Spain; Universidad Complutense de Madrid, Madrid, Spain.
- 3 Pathology Department, Hospital Universitario Infanta Leonor, Gran vía del este, 80, 28031 Madrid, Spain; Universidad Complutense de Madrid, Madrid, Spain.
No abstract available
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Humans
-
Lung Neoplasms* / drug therapy
-
Vitiligo* / chemically induced
Substances
-
Antibodies, Monoclonal
-
durvalumab